Jelly Force Official Website › Articles › Honest safety analysis

Honest safety analysis

Ashwagandha and the liver: a quiet safety file

By the Jelly Force Team at Jellyfoarce · Published 2026-09-20 · Last updated 2026-11-04 · Reviewed by Dr. Dyan Hes, MD

Why this article is on the seller's own website

Because a reader who finds this out afterwards was right not to trust the page that hid it, and because the thing being described is manageable once it is known.

Ashwagandha is one of the nine ingredients on this bottle’s panel. It has more randomised trials behind it than any other herb on it, and the best-documented safety file on the label.

What the published record holds

A 2026 scoping review searched the peer-reviewed clinical literature through December 2025 for reports of liver injury associated with ashwagandha, whether in single-ingredient products or in formulations containing it. Thirteen publications met its criteria, describing 25 patients across several parts of the world.

The pattern the review describes is consistent enough to have a shape:

• Injury typically developed after weeks of use rather than after a single exposure.
• The biochemical picture was usually cholestatic or mixed; purely hepatocellular injury was less common.
• The common presentation was jaundice and itching.
• Where formal causality assessment was applied, ashwagandha was generally rated probable or likely as the cause.
• Most patients recovered after stopping, usually over weeks to months.
• The severe end: one case of acute liver failure requiring transplantation, and three deaths — all three in people who already had cirrhosis and decompensated.

The LiverTox monograph, maintained by the National Institute of Diabetes and Digestive and Kidney Diseases, covers the same ground for a clinical audience. The NCCIH page does it for a general reader, and a 2026 critical review of the herb's adverse effects adds gastrointestinal effects, immune hypersensitivity and endocrine disruption to the list, with cytochrome P450 metabolism proposed as one route to reactive intermediates.

Summarised from the scoping review and the LiverTox monograph, both linked at the foot of this article.

Keeping it in proportion

Two things need saying in the same breath as the paragraphs above, or this article becomes its own kind of dishonesty.

The first is scale. Twenty-five reported patients is a small number against the volume of ashwagandha sold worldwide, and case reporting is a system that captures the unusual rather than the typical. Most of the reported patients recovered after stopping.

The second is amount. Most of the cases involve single-ingredient ashwagandha products at amounts far above the 5 mg or less that its place in this 82 mg blend allows. Nobody has established a threshold below which nothing happens, which is why the reaction is described as idiosyncratic, but the exposure here is at the very low end of anything reported.

So the honest position is neither alarm nor silence. It is that a specific, documented, manageable risk exists, that it attaches to one named ingredient, and that two groups of people should ask before starting.

Who should ask before starting

1. Anyone with liver disease of any kind, and especially anyone with cirrhosis. This is the clearest exclusion on this label and it comes directly from the three deaths in the review.
2. Anyone with a history of drug-induced or herb-induced liver injury. A previous idiosyncratic reaction is the best predictor anybody has.
3. Anyone taking a medicine with its own hepatic profile, which is a long list and is exactly the sort of question a pharmacist answers in thirty seconds.
4. Anyone with a thyroid condition. A reported case of painless thyroiditis and a modest T4 rise across 23 trials are both on the record.
5. Anyone who develops jaundice, dark urine or persistent itching while taking it. Stop and be seen; that is the whole instruction.

How a herb ends up in a case report at all

Worth understanding, because it explains both why the number is small and why it should not be dismissed.

Idiosyncratic liver injury is not a dose effect in the ordinary sense. It is a reaction that happens in a small number of people for reasons that are largely individual — genetics, enzyme variation, what else is being taken, what else the liver is dealing with. The 2026 critical review proposes metabolism through cytochrome P450 enzymes as one route, producing reactive intermediates and oxidative stress.

That has two consequences a reader should hold together. The first is that a small serving is not a guarantee, because the mechanism is not a simple threshold. The second is that the base rate is low, because most people take these products without incident and the literature only records the ones that went wrong.

It also explains the reporting lag. A case report exists because a clinician thought to ask what a patient was taking, wrote it up, and got it published. Everything about that chain under-counts, which is why twenty-five patients in thirteen publications is a signal rather than a census.

• Reported after weeks, not hours. The exposure pattern is a routine, not a single dose.
• Usually reversible. Stopping is the treatment in most of the reported cases.
• Worse with existing liver disease. Every death in the review was in somebody who already had cirrhosis.
• Under-counted by construction. Case reporting captures the unusual and the noticed.
• Not predictable in advance. Which is why the advice is to know the signals rather than to calculate a safe amount.

What the rest of this bottle's safety file looks like

Ashwagandha is the loudest entry and it is not the only one. Set beside the other eight names on the panel, the picture is uneven in a way worth seeing whole.

An ingredient with no safety file usually has no efficacy file either. The two absences travel together, and both are information.

What this means for reading any label

Ashwagandha is in an enormous number of products, most of which do not mention any of the above. A reader who now knows to look for the word has something genuinely useful, and it transfers well beyond this bottle.

It is also a reminder that natural and safe are unrelated concepts. The all-natural emblem on this packaging, like the one on most packaging in this aisle, carries no agreed definition and says nothing about a liver. The ingredient with the best trials on this label is also the one with the safety file, and those two facts are not a coincidence: an ingredient nobody has studied has no safety file either. Green tea extract, on the panel and absent from the advertising, is the other name here with a liver record.